1015 Capital Partners’s DexCom DXCM Stock Holding History

1015 Capital Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$943	Hold	14	–	–	﹤0.01%	461
2026 Q1	$879	Buy	14 +5	+56%	+$348	﹤0.01%	450
2025 Q4	$597	Buy	+9	New	+$582	﹤0.01%	531

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

1015 Capital Partners's DXCM Position: Q2 2026 in Review

1015 Capital Partners held its DexCom (DXCM) position steady in Q2 2026 at 14 shares worth $943. The position accounts for ﹤0.01% of the portfolio, ranked #461.

1015 Capital Partners first reported a position in DXCM in Q4 2025 and has held it in 3 quarters since. 964 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

1015 Capital Partners held 14 shares of DexCom worth $943 as of Q2 2026.
1015 Capital Partners left its DexCom share count unchanged in Q2 2026.
DexCom made up ﹤0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #461 holding.
1015 Capital Partners first reported a position in DexCom in Q4 2025 and has held it in 3 quarters since.
964 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.